Category: pharmacological
Aliases: Fosamax
Aminobisphosphonate — incorporates into hydroxyapatite + inhibits farnesyl pyrophosphate synthase in osteoclasts → osteoclast apoptosis → reduced bone resorption. First-line oral therapy for postmenopausal osteoporosis. Esophageal irritation requires upright positioning + 30 min fast post-dose.
PO: 240h